Neuronetics Financials
| STIM Stock | USD 1.42 0.13 8.39% |
Neuronetics Balance Sheet Chart
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.03 | 2.14 |
|
|
The essential information of the day-to-day investment outlook for Neuronetics includes many different criteria found on its balance sheet. An individual investor should research Neuronetics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Neuronetics.
Net Income |
|
Neuronetics | Select Account or Indicator | Build AI portfolio with Neuronetics Stock |
Neuronetics Stock Summary
Neuronetics competes with Prenetics Global, Nyxoah, Atlantic International, OmniAb, and Perspective Therapeutics. Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania. Neuronetics operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 198 people.Specialization | Health Care, Health Care Equipment & Services |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US64131A1051 |
| Business Address | 3222 Phoenixville Pike, |
| Sector | Health Care Equipment & Supplies |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | neurostar.com/neuronetics |
| Phone | 610 640 4202 |
| Currency | USD - US Dollar |
Neuronetics Key Financial Ratios
| Return On Equity | -2.19 | ||||
| Profit Margin | (0.34) % | ||||
| Operating Margin | (0.20) % | ||||
| Price To Sales | 0.82 X | ||||
| Revenue | 74.89 M |
Neuronetics Key Balance Sheet Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Total Assets | 141.2M | 116.9M | 115.8M | 140.9M | 162.0M | 106.9M | |
| Other Current Liab | 7.6M | 14.2M | 11.8M | 13.8M | 15.9M | 10.1M | |
| Other Liab | 2.1M | 1.7M | 1.5M | 829K | 746.1K | 1.2M | |
| Net Tangible Assets | 46.7M | 25.5M | 85.2M | 57.1M | 65.6M | 68.9M | |
| Net Debt | (54.6M) | (30.6M) | 2.8M | 63.2M | 72.6M | 76.3M | |
| Retained Earnings | (308.7M) | (345.9M) | (376.1M) | (419.8M) | (377.8M) | (396.7M) | |
| Accounts Payable | 4.3M | 2.4M | 4.8M | 11.1M | 12.7M | 13.4M | |
| Cash | 94.1M | 70.3M | 59.7M | 19.5M | 22.4M | 21.3M | |
| Other Assets | 12.9M | 167.1M | 9.2M | 1.0 | 1.15 | 1.09 | |
| Long Term Debt | 35.3M | 22.8M | 59.3M | 55.2M | 63.4M | 37.0M | |
| Net Receivables | 7.8M | 13.8M | 17.8M | 24.3M | 27.9M | 29.3M | |
| Inventory | 6.6M | 8.9M | 8.1M | 4.2M | 4.9M | 5.0M | |
| Other Current Assets | 4.6M | 4.2M | 7.3M | 9.9M | 11.4M | 12.0M | |
| Total Liab | 56.0M | 59.8M | 81.6M | 109.1M | 98.2M | 79.3M | |
| Total Current Assets | 115.3M | 98.8M | 93.8M | 58.1M | 66.8M | 84.8M | |
| Short Term Debt | 670K | 13.9M | 845K | 4.8M | 4.3M | 6.7M | |
| Common Stock | 264K | 273K | 291K | 557K | 640.6K | 672.6K | |
| Net Invested Capital | 120.5M | 93.0M | 93.5M | 82.9M | 95.3M | 64.3M | |
| Net Working Capital | 99.6M | 65.6M | 74.0M | 26.9M | 24.2M | 23.0M | |
| Intangible Assets | 2.5M | 3.6M | 4.2M | 19.6M | 22.5M | 23.7M |
Neuronetics Key Income Statement Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Net Interest Income | (4.0M) | (4.3M) | (5.4M) | (7.3M) | (6.6M) | (6.9M) | |
| Interest Expense | 3.3M | 3.6M | 5.4M | 7.3M | 8.4M | 4.4M | |
| Total Revenue | 55.3M | 65.2M | 71.3M | 74.9M | 86.1M | 61.9M | |
| Gross Profit | 43.7M | 49.7M | 51.7M | 54.2M | 62.3M | 46.8M | |
| Operating Income | (27.6M) | (35.1M) | (30.6M) | (34.6M) | (31.1M) | (32.7M) | |
| Ebit | (27.9M) | (33.6M) | (24.8M) | (36.4M) | (32.8M) | (34.4M) | |
| Research Development | 7.9M | 9.3M | 9.5M | 12.8M | 14.7M | 10.6M | |
| Ebitda | (26.8M) | (32.0M) | (22.8M) | (34.4M) | (30.9M) | (32.5M) | |
| Cost Of Revenue | 11.7M | 15.5M | 19.6M | 20.7M | 23.8M | 15.1M | |
| Income Before Tax | (31.2M) | (37.2M) | (30.2M) | (43.7M) | (39.4M) | (41.3M) | |
| Net Income | (31.2M) | (37.2M) | (30.2M) | (43.7M) | (39.3M) | (41.3M) | |
| Income Tax Expense | 4.4M | 2.0M | (24K) | (14K) | (12.6K) | (12.0K) |
Neuronetics Key Cash Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Change To Inventory | (3.4M) | (2.6M) | (1.1M) | 3.2M | 3.6M | 3.8M | |
| Investments | (9.8M) | 10M | (1.3M) | (2.4M) | (2.8M) | (2.6M) | |
| Change In Cash | 45.2M | (23.8M) | (10.7M) | (40.2M) | (36.2M) | (34.4M) | |
| Net Borrowings | 0.0 | (91K) | 23.8M | (2.5M) | (2.9M) | (2.8M) | |
| Free Cash Flow | (30.3M) | (34.0M) | (34.4M) | (32.5M) | (29.2M) | (30.7M) | |
| Depreciation | 1.1M | 1.6M | 2.0M | 2.1M | 2.4M | 1.3M | |
| Other Non Cash Items | 918K | 1.1M | 2.9M | 11.9M | 13.6M | 14.3M | |
| Capital Expenditures | 2.4M | 3.3M | 2.4M | 1.5M | 1.7M | 1.6M | |
| Net Income | (31.2M) | (37.2M) | (30.2M) | (43.7M) | (39.4M) | (41.3M) | |
| End Period Cash Flow | 94.1M | 70.3M | 59.7M | 19.5M | 22.4M | 21.3M | |
| Change To Netincome | 3.4M | 4.4M | 8.8M | 8.7M | 10.1M | 10.6M |
Neuronetics Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Neuronetics's current stock value. Our valuation model uses many indicators to compare Neuronetics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Neuronetics competition to find correlations between indicators driving Neuronetics's intrinsic value. More Info.Neuronetics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Neuronetics' Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Neuronetics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Most indicators from Neuronetics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Neuronetics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Neuronetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Neuronetics Stock, please use our How to Invest in Neuronetics guide.As of the 7th of February 2026, Selling General Administrative is likely to drop to about 21 M. In addition to that, Sales General And Administrative To Revenue is likely to drop to 0.26
| 2025 | 2026 (projected) | Depreciation And Amortization | 2.4M | 1.3M | Interest Income | 4.2M | 3.3M |
Neuronetics fundamental ratios Correlations
Click cells to compare fundamentals
Neuronetics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Neuronetics fundamental ratios Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Total Assets | 141.2M | 116.9M | 115.8M | 140.9M | 162.0M | 106.9M | |
| Other Current Liab | 7.6M | 14.2M | 11.8M | 13.8M | 15.9M | 10.1M | |
| Other Liab | 2.1M | 1.7M | 1.5M | 829K | 746.1K | 1.2M | |
| Net Tangible Assets | 46.7M | 25.5M | 85.2M | 57.1M | 65.6M | 68.9M | |
| Net Debt | (54.6M) | (30.6M) | 2.8M | 63.2M | 72.6M | 76.3M | |
| Retained Earnings | (308.7M) | (345.9M) | (376.1M) | (419.8M) | (377.8M) | (396.7M) | |
| Accounts Payable | 4.3M | 2.4M | 4.8M | 11.1M | 12.7M | 13.4M | |
| Cash | 94.1M | 70.3M | 59.7M | 19.5M | 22.4M | 21.3M | |
| Other Assets | 12.9M | 167.1M | 9.2M | 1.0 | 1.15 | 1.09 | |
| Long Term Debt | 35.3M | 22.8M | 59.3M | 55.2M | 63.4M | 37.0M | |
| Net Receivables | 7.8M | 13.8M | 17.8M | 24.3M | 27.9M | 29.3M | |
| Inventory | 6.6M | 8.9M | 8.1M | 4.2M | 4.9M | 5.0M | |
| Other Current Assets | 4.6M | 4.2M | 7.3M | 9.9M | 11.4M | 12.0M | |
| Total Liab | 56.0M | 59.8M | 81.6M | 109.1M | 98.2M | 79.3M | |
| Total Current Assets | 115.3M | 98.8M | 93.8M | 58.1M | 66.8M | 84.8M | |
| Short Term Debt | 670K | 13.9M | 845K | 4.8M | 4.3M | 6.7M | |
| Common Stock | 264K | 273K | 291K | 557K | 640.6K | 672.6K | |
| Net Invested Capital | 120.5M | 93.0M | 93.5M | 82.9M | 95.3M | 64.3M | |
| Net Working Capital | 99.6M | 65.6M | 74.0M | 26.9M | 24.2M | 23.0M | |
| Intangible Assets | 2.5M | 3.6M | 4.2M | 19.6M | 22.5M | 23.7M |
Today, most investors in Neuronetics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Neuronetics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Neuronetics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Neuronetics February 7, 2026 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Neuronetics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Neuronetics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Neuronetics based on widely used predictive technical indicators. In general, we focus on analyzing Neuronetics Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Neuronetics's daily price indicators and compare them against related drivers.
| Information Ratio | (0.11) | |||
| Maximum Drawdown | 34.69 | |||
| Value At Risk | (9.52) | |||
| Potential Upside | 10.55 |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Neuronetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Neuronetics Stock, please use our How to Invest in Neuronetics guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Will Health Care Equipment & Supplies sector continue expanding? Could Neuronetics diversify its offerings? Factors like these will boost the valuation of Neuronetics. If investors know Neuronetics will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Neuronetics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.83) | Revenue Per Share | Quarterly Revenue Growth 1.013 | Return On Assets | Return On Equity |
Neuronetics's market price often diverges from its book value, the accounting figure shown on Neuronetics's balance sheet. Smart investors calculate Neuronetics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Neuronetics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Neuronetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuronetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuronetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.